Compare · ENGN vs RVMD
ENGN vs RVMD
Side-by-side comparison of enGene Therapeutics Inc. (ENGN) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENGN and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $45.31B, about 361.7x ENGN ($125.3M).
- RVMD has been more active in the news (11 items in the past 4 weeks vs 6 for ENGN).
- RVMD has more recent analyst coverage (25 ratings vs 23 for ENGN).
- Company
- enGene Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.87+3.31%
- $211.21-0.17%
- Market cap
- $125.3M
- $45.31B
- 1M return
- +6.86%
- -
- 1Y return
- -56.00%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 11
- Recent ratings
- 23
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ENGN
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- enGene Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
- SEC Form 3 filed by new insider Chinoporos Constantine
- New insider Richton Kathleen P. claimed ownership of 6,900 shares (SEC Form 3)
- SEC Form SCHEDULE 13G filed by enGene Therapeutics Inc.
- enGene Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits